Literature DB >> 18537177

Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.

Cristina Bosetti1, Fabio Levi, Paolo Boffetta, Franca Lucchini, Eva Negri, Carlo La Vecchia.   

Abstract

UNLABELLED: Upward trends in mortality from hepatocellular carcinoma (HCC) were recently reported in the United States and Japan. Comprehensive analyses of most recent data for European countries are not available. Age-standardized (world standard) HCC rates per 100,000 (at all ages, at age 20-44, and age 45-59 years) were computed for 23 European countries over the period 1980-2004 using data from the World Health Organization. Joinpoint regression analysis was used to identify significant changes in trends, and annual percent change were computed. Male overall mortality from HCC increased in Austria, Germany, Switzerland, and other western countries, while it significantly decreased over recent years in countries such as France and Italy, which had large upward trends until the mid-1990s. In the early 2000s, among countries allowing distinction between HCC and other liver cancers, the highest HCC rates in men were in France (6.8/100,000), Italy (6.7), and Switzerland (5.9), whereas the lowest ones were in Norway (1.0), Ireland (0.8), and Sweden (0.7). In women, a slight increase in overall HCC mortality was observed in Spain and Switzerland, while mortality decreased in several other European countries, particularly since the mid-1990s. In the early 2000s, female HCC mortality rates were highest in Italy (1.9/100,000), Switzerland (1.8), and Spain (1.5) and lowest in Greece, Ireland, and Sweden (0.3). In most countries, trends at age 45-59 years were consistent with overall ones, whereas they were more favorable at age 20-44 years in both sexes.
CONCLUSION: HCC mortality remains largely variable across Europe. Favorable trends were observed in several European countries mainly over the last decade, particularly in women and in young adults.

Entities:  

Mesh:

Year:  2008        PMID: 18537177     DOI: 10.1002/hep.22312

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  60 in total

1.  Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.

Authors:  Mauro Borzio; Elena Dionigi; Angelo Rossini; Anna Toldi; Giampiero Francica; Fabio Fornari; Andrea Salmi; Fabio Farinati; Susanna Vicari; Massimo Marignani; Fulvia Terracciano; Barbara Ginanni; Rodolfo Sacco
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

2.  A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial.

Authors:  Takahiro Yamasaki; Satoe Hamabe; Issei Saeki; Yohei Harima; Yuhki Yamaguchi; Koichi Uchida; Shuji Terai; Isao Sakaida
Journal:  J Gastroenterol       Date:  2010-08-25       Impact factor: 7.527

3.  Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation.

Authors:  Ming-An Yu; Ping Liang; Xiao-Ling Yu; Zhi-Yu Han; Xue-Juan Dong; Y U Wang; Chao Cheng; Xin Li
Journal:  Exp Ther Med       Date:  2015-08-14       Impact factor: 2.447

Review 4.  Diagnosis and treatment of hepatocellular carcinoma: An update.

Authors:  Javier Tejeda-Maldonado; Ignacio García-Juárez; Jonathan Aguirre-Valadez; Adrián González-Aguirre; Mario Vilatobá-Chapa; Alejandra Armengol-Alonso; Francisco Escobar-Penagos; Aldo Torre; Juan Francisco Sánchez-Ávila; Diego Luis Carrillo-Pérez
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Disease Burden of Hepatocellular Carcinoma: A Global Perspective.

Authors:  Mehmet Sayiner; Pegah Golabi; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

6.  Management of hepatocellular carcinoma: Enlightening the gray zones.

Authors:  Andrea Mancuso
Journal:  World J Hepatol       Date:  2013-06-27

7.  Definitive locoregional therapy (LRT) versus bridging LRT and liver transplantation with wait-and-not-treat approach for very early stage hepatocellular carcinoma.

Authors:  Peiman Habibollahi; Stephen Hunt; Therese Bitterman; Terence P Gade; Michael C Soulen; Gregory Nadolski
Journal:  Diagn Interv Radiol       Date:  2018-07       Impact factor: 2.630

8.  Nano-LC-Q-TOF Analysis of Proteome Revealed Germination of Aspergillus flavus Conidia is Accompanied by MAPK Signalling and Cell Wall Modulation.

Authors:  Shraddha Tiwari; Raman Thakur; Gunjan Goel; Jata Shankar
Journal:  Mycopathologia       Date:  2016-08-30       Impact factor: 2.574

Review 9.  Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides.

Authors:  Jean-Luc Raoul; Eveline Boucher; Yan Rolland; Etienne Garin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

Review 10.  Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment.

Authors:  Giuseppe Castello; Susan Costantini; Stefania Scala
Journal:  J Transl Med       Date:  2010-11-03       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.